Cargando…

Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems

In a mixed‐vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Ecli...

Descripción completa

Detalles Bibliográficos
Autores principales: Laub, Wolfram U., Merz, Brandon, Kishore, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984463/
https://www.ncbi.nlm.nih.gov/pubmed/33619852
http://dx.doi.org/10.1002/acm2.13180
_version_ 1783668069378293760
author Laub, Wolfram U.
Merz, Brandon
Kishore, Monica
author_facet Laub, Wolfram U.
Merz, Brandon
Kishore, Monica
author_sort Laub, Wolfram U.
collection PubMed
description In a mixed‐vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Eclipse are discussed. In each TPS static field, Intensity‐Modulated Radiation Therapy (IMRT) step and shoot, and Volumetric‐Modulated Arc Therapy (VMAT) plans for flattened and flattening‐filter free photon beams of all available energies were evaluated for field sizes >3 × 3. To compare passing rates, identical beam model validation plans were calculated in each TPS. Eclipse, Monaco, and Pinnacle beam models passed validation measurements in homogeneous materials for a variety of treatment fields, including static, IMRT, and VMAT. In the case of Eclipse, the “dosimetric leaf gap” parameter was found to be critical for passing rates of VMAT plans. The source size parameter plays an important role as well for small fields. In the case of Pinnacle the multileaf collimator offset table needed to be optimized for better VMAT QA results. Each of the investigated treatment planning systems met the criteria to be used clinically in conjunction with Elekta Versa HD linear accelerators. It can be of great advantage to have the option to operate a TPS and linear accelerator from different vendors, as decisions surrounding linear accelerator or TPS purchases are very complicated and not just limited to technical considerations.
format Online
Article
Text
id pubmed-7984463
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79844632021-03-25 Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems Laub, Wolfram U. Merz, Brandon Kishore, Monica J Appl Clin Med Phys Radiation Oncology Physics In a mixed‐vendor radiation oncology environment, it is advantageous if the department's treatment planning system (TPS) supports the linear accelerators of different vendors. In this publication beam data collection and modeling for the Versa HD linear accelerator in Monaco, Pinnacle, and Eclipse are discussed. In each TPS static field, Intensity‐Modulated Radiation Therapy (IMRT) step and shoot, and Volumetric‐Modulated Arc Therapy (VMAT) plans for flattened and flattening‐filter free photon beams of all available energies were evaluated for field sizes >3 × 3. To compare passing rates, identical beam model validation plans were calculated in each TPS. Eclipse, Monaco, and Pinnacle beam models passed validation measurements in homogeneous materials for a variety of treatment fields, including static, IMRT, and VMAT. In the case of Eclipse, the “dosimetric leaf gap” parameter was found to be critical for passing rates of VMAT plans. The source size parameter plays an important role as well for small fields. In the case of Pinnacle the multileaf collimator offset table needed to be optimized for better VMAT QA results. Each of the investigated treatment planning systems met the criteria to be used clinically in conjunction with Elekta Versa HD linear accelerators. It can be of great advantage to have the option to operate a TPS and linear accelerator from different vendors, as decisions surrounding linear accelerator or TPS purchases are very complicated and not just limited to technical considerations. John Wiley and Sons Inc. 2021-02-22 /pmc/articles/PMC7984463/ /pubmed/33619852 http://dx.doi.org/10.1002/acm2.13180 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Laub, Wolfram U.
Merz, Brandon
Kishore, Monica
Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
title Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
title_full Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
title_fullStr Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
title_full_unstemmed Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
title_short Commissioning of a Versa HD(TM) linear accelerator for three commercial treatment planning systems
title_sort commissioning of a versa hd(tm) linear accelerator for three commercial treatment planning systems
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984463/
https://www.ncbi.nlm.nih.gov/pubmed/33619852
http://dx.doi.org/10.1002/acm2.13180
work_keys_str_mv AT laubwolframu commissioningofaversahdtmlinearacceleratorforthreecommercialtreatmentplanningsystems
AT merzbrandon commissioningofaversahdtmlinearacceleratorforthreecommercialtreatmentplanningsystems
AT kishoremonica commissioningofaversahdtmlinearacceleratorforthreecommercialtreatmentplanningsystems